期刊文献+

芦丁固体分散体的制备及其溶出性能研究 被引量:7

Preparation of rutin solid dispersion and dissolution properties
下载PDF
导出
摘要 目的:采用固体分散技术,提高芦丁在水中的溶出,增强生物利用度。方法:采用7种载体(β-环糊精、聚乙烯吡咯烷酮、羟丙基纤维素、聚乙二醇6000、琥珀酸、乳糖、泊洛沙姆188),3种常用方法制备固体分散体,确定制备所选择的载体及方法;利用正交试验设计,以15 min时芦丁溶出度为指标成分,优化制备的具体工艺。并采用差示扫描量热法对分散体进行物相鉴别。利用相似因子法对固体分散体与其它混合物进行统计学评价;研究不同温度、不同浓度的固体分散体的溶解度,从化学热力学角度探讨固体分散体的形成机制。结果:以聚乙二醇6000为载体,溶剂熔融法,熔融时间1min、药物与载体比例1∶9、加热温度70℃为最佳方案;差示扫描量热法显示制备的固体分散体符合要求。相似因子法显示,固体分散体芦丁是分散在载体中。结论:聚乙二醇6000是提高芦丁溶出的理想载体,并表明固体分散体的形成为自发过程。 AIM: To improve the dissolution of rutin solid dispersions(RSD),and enhance bioavailability.METHODS: RSD were prepared respectively by three methods with seven carriers(β-cyclodextrin,PVP,HPMC;Polyglycol 6000,succinic acid,lactose,and poloxamer 188).With the method of orthogonal experiment design,choosing the 15 minute solubility of rutin as the index and the specific progress optimization for preparation,powder differential scanning calorimetry(DSC) were used to examine the physical and chemical characteristics of the solid dispersions.The similarity factor was used for statistical evaluation of RSD,and the other mixture.The solubility of RSD with different temperate and concent was studied in order to be discussed by the thermodynamic theory.RESULTS: The result showed that every method and carrier could enhance the solubility of RSD,expecial the PEG6000 as carrier and solvent evaporation-fusion method.The optimized preparation conditions were that the fusion time was 1 min,the ratio of rutin to carrier was 1 ∶ 9,temperature was 70 ℃.DSC showed that RSP was required.Method of similarity factor showed that rutin was dispersed in carrier.CONCLUSION: PEG6000 is a very useful carrier for improvement in the solubility of rutin and solution was a spontaneous process.
出处 《中成药》 CAS CSCD 北大核心 2010年第12期2071-2075,共5页 Chinese Traditional Patent Medicine
基金 "重大新药创制"科技重大专项(适宜于中药复方多组合特色的缓控释给药系统的关键技术研究 2009ZX09502-008) 中药生产技术及过程控制技术标准平台(2009ZX09308-003) 教育部博士点基金(20090013110007)
关键词 芦丁 聚乙二醇6000 固体分散体 rutin PEG6000 solid dispersions
  • 相关文献

参考文献3

二级参考文献13

  • 1颜耀东,张家相,黄晓洁,倪弘,王虹.黄芩甙共沉淀物和固体分散物的研究[J].中国药学杂志,1993,28(7):411-414. 被引量:6
  • 2中华人民共和国药典委员会.中国药典(2部)[M].北京:化学工业出版社,1995.912.
  • 3陆锦芳 王妙珍 等.布洛芬-PVP共沉淀物的制备及溶出度特性的研究[J].中国药学杂志,1989,24(6):346-346.
  • 4奚念珠 等.药剂学(第3版)[M].北京:人民卫生出版社,1994,7.271.
  • 5胡昌良.应用共沉淀物增强难溶性药物的生物利用度[J].国外医学:药学分册,1982,(4):232-232.
  • 6S. George Carruthers, Brian B Hoffan, Kenneth L Melmon, et al. Clinical Pharmacology[M]. 4nd ed. Beijing:McGraw-Hill, 2000. 529 - 551.
  • 7Bertram GKatzung. Basic & Clinical Pharmacology[M]. 8nd ed. Beijing:McGraw-Hill, 2001. 711 - 734.
  • 8Rockville MD. FDA Guidance for Industry: immediate release solid dosage forms: scale-up and post approval changes ( SUPAC-IR ) : chemistry, manufacturing and controls, in vitro dissolution testing and in vivo bioequivalence documentation [ EB/OL ]. http://www, fda.gov/cder/guidance/index, htm, 1995 - 11.
  • 9Rockville MD. FDA Guidance for Industry: dissolution testing of immediate release solid dosage forms [ EB/OL]. http://www, fda. gov/cder/guidance/index.htm, 1997 - 08.
  • 10Rockville MD. FDA Guidance for Industry: extended release oral dosage forms: development, evaluation and application of in vitro/in vivo correlation [EB/OL].http://www, fda. gov/cder/guidance/index, htm, 1997 -09.

共引文献150

同被引文献71

引证文献7

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部